Veeva Systems (VEEV) Stock Slides as Market Rises: Facts to Know Before You Trade
Veeva Systems (VEEV) closed the most recent trading day at $158.27, moving 4.06% from the previous trading session.
VEEV - Veeva Systems Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$276.57
DETAILS
HIGH:
$333.00
LOW:
$205.00
MEDIAN:
$283.00
CONSENSUS:
$276.57
UPSIDE:
72.67%
Stock News
Veeva Systems: AI Fears Look Overdone, The Selloff Creates An Opportunity
Veeva Systems (VEEV) is rated Buy, trading at multi-year lows despite robust 16% revenue growth, 44% non-GAAP margins, and conservative FY27 guidance. AI disruption fears are overstated for VEEV's FDA-regulated Development Cloud, which comprises 55% of revenue and remains highly defensible due to regulatory switching costs. Vault CRM migration is progressing, reducing Salesforce dependency and enhancing control over product roadmap and AI integration; CRM competition is real but not existential.
Veeva Systems (VEEV) Rises Yet Lags Behind Market: Some Facts Worth Knowing
The latest trading day saw Veeva Systems (VEEV) settling at $164.96, representing a +1.01% change from its previous close.
Veeva Systems' RTSM Momentum Signals Another Long-Term Growth Driver
VEEV benefits from RTSM traction with major pharma wins, strengthening its clinical software strategy and long-term R&D growth outlook.
Here's Why Veeva Systems (VEEV) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss.
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circling the wreckage.
Veeva Systems Expands AI and Vault CRM Momentum: Time to Buy or Hold?
VEEV expands Vault CRM adoption and AI capabilities with Roche and BioMarin partnerships as life sciences firms modernize workflows.
Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial
argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical PLEASANTON, Calif., May 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will showcase the future of agentic commercial in biopharma at Veeva Commercial Summit, May 19-20 in Boston.
Veeva Systems (VEEV) Stock Falls Amid Market Uptick: What Investors Need to Know
Veeva Systems (VEEV) closed the most recent trading day at $156.33, moving 1.94% from the previous trading session.
Veeva to Release Fiscal 2027 First Quarter Results on June 3, 2026
PLEASANTON, Calif., May 13, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its first quarter ending April 30, 2026 after market close on June 3, 2026.
VEEV Boosts MedTech Quality Management With Smith+Nephew Partnership
Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.
Can Veeva Systems' Expanding Partnerships Drive Further Upside?
VEEV is expanding partnerships, growing Vault CRM adoption and boosting AI capabilities with its Ostro acquisition.
A Look at Veeva Systems Inc (VEEV) After 4.2% Decline -- GF Value $280.52 vs Price $159.33
On May 11, 2026, Veeva Systems Inc (VEEV) shares fell 4.2% today, bringing the current price to $159.33. The stock has experienced a 52-week range between $148.
Smith+Nephew Establishes Unified Quality Foundation Worldwide with Veeva Quality Cloud
Quality transformation drives compliance and operational efficiency PLEASANTON, Calif., May 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Smith+Nephew is unifying quality management with Veeva Quality Cloud.
Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know
Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Accumulus Technologies Announces Live Integration with Veeva RIM, Enabling Seamless RIM to Regulator Connection
The Accumulus platform brings global regulatory collaboration directly into Veeva RIM The Accumulus platform brings global regulatory collaboration directly into Veeva RIM
Veeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $167.29, denoting a -2.28% move from the preceding trading day.
3 Medical Info Systems Stocks Riding the GenAI Wave in a Tough Market
Doximity, Veeva and Omnicell ride surging GenAI adoption in healthcare, tapping digital demand despite market pressure and rising cybersecurity risks.
Price Targets
Veeva price target lowered to $275 from $325 at Oppenheimer
$275.00
(was $172.17)
Oppenheimer
Veeva upgraded to Equal Weight from Underweight at Morgan Stanley
$205.00
(was $174.11)
Morgan Stanley
Veeva price target lowered to $295 from $325 at Mizuho
$295.00
(was $190.80)
Mizuho Securities
Veeva assumed with a Sell at Goldman Sachs
$215.00
(was $233.21)
Adam Hotchkiss
·
Goldman Sachs
Veeva price target lowered to $283 from $319 at Baird
$283.00
(was $243.69)
Robert W. Baird
Morgan Stanley says Salesforce comments show competition 'heating up' for Veeva
$222.00
(was $244.22)
Craig Hettenbach
·
Morgan Stanley
Veeva price target lowered to $333 from $341 at Wells Fargo
$333.00
(was $235.74)
Stan Berenshteyn
·
Wells Fargo
Veeva Systems (VEEV) PT Lowered to $330 at Jefferies
$330.00
(was $244.06)
David Windley
·
Jefferies
Veeva price target raised to $319 from $314 at Baird
$319.00
(was $270.50)
Robert W. Baird
Veeva price target lowered to $280 from $310 at UBS
$280.00
(was $270.50)
UBS
Veeva price target lowered to $280 from $300 at Canaccord
$280.00
(was $270.50)
Canaccord Genuity
Veeva price target lowered to $305 from $325 at Barclays
$305.00
(was $270.50)
Barclays
Veeva price target raised to $325 from $295 at Mizuho
$325.00
(was $272.33)
Mizuho Securities
Veeva price target raised to $325 from $300 at Barclays
$325.00
(was $280.05)
Barclays
Veeva price target raised to $355 from $300 at Needham
$355.00
(was $280.07)
Needham
Veeva price target raised to $314 from $310 at Baird
$314.00
(was $279.95)
Robert W. Baird
Veeva Systems (VEEV) PT Raised at Piper Sandler on 'Improving Visibility'
$355.00
(was $280.32)
Brent Bracelin
·
Piper Sandler
Veeva price target raised to $310 from $285 at UBS
$310.00
(was $272.33)
UBS
Veeva price target raised to $297 from $284 at TD Cowen
$297.00
(was $272.33)
UBS
Veeva price target raised to $340 from $335 at BTIG
$340.00
(was $272.33)
UBS